Keytruda (pembrolizumab)

pCPA File Number: 22294
Negotiation Status:
Concluded with an LOI
For the treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy.
Merck Canada Inc.
CDA-AMC Project Number:
pCPA Engagement Letter Issued:
Negotiation Process Concluded: